---

Gideon Goldstein D r. Goldstein discovered and developed a unique monoclonal antibody, OKT3, that has saved many patients from the otherwise inevitable immune destruction of their transplanted kidney, liver or heart. The treatment is used with 60 percent of all patients undergoing transplantation. Othorclone OKT3 is produced by Ortho Biotech and is marketed in the United States by Ortho Biotech and in 29 countries throughout the world by Johnson and Johnson local affiliate companies generally operating under the name CILAG. He also discovered other monoclonal antibodies that uniquely identify certain circulating cells in man, and are invaluable in diagnosis of immunological changes in man, especially in regard to AIDS. These include OKT4 (CD4) and OKT8 (CD8). The use of OFT4 is noteworthy in the treatment of AIDS, where it has become the most important single criterion in assessing disease, status, prognosis and response to therapy. Dr. Goldstein, born in Kaunas, Lithuania, holds 29 patents. He came to the United States in 1967 as a visiting scientist for the National Institute of Health in Bethseda, Md. The Gideon Goldstein Academic Achievement Award Immunology was established at the Kaplan Cancer Center, New York University School of Medicine, in 1987.